magnifying glass
logo for Bacainn Therapeutics

Bacainn Therapeutics

Get Full Access

Description

Bacainn Therapeutics is developing novel therapies that target the innate immune system to address uncontrolled inflammation in serious gastrointestinal and res... Read More

Headquarters

Headquarters:

530 Virginia Rd, Ste 300, Concord, Massachusetts, 01742, United States
Employees

Employees:

<25
Revenue

Revenue:

<$5 Million
Bacainn Therapeutics's Social Media
SIC Code 72,729
NAICS Code 81299,81
Popular Searches:

Bacainn Therapeutics Inc

Bacainn Therapeutics , Inc.

Bacainn Therapeutics

Bacainn Therapeutics's Org Chart

Ronald Farquhar
Ronald Farquhar

Chief Executive Officer & Co-Founde...

PhonePhoneEmailEmail
Mustafa Noor
Mustafa Noor

Chief Medical Officer

PhonePhoneEmailEmail

PhonePhoneEmailEmail

PhonePhoneEmailEmail

PhonePhoneEmailEmail
Illustration of an envelope

Bacainn Therapeutics's Tech Stack

jQuery Migrate

By

jQuery

Microsoft Exchange Online

By

Microsoft

Cloudflare Security

By

Cloudflare

Business Wire

By

Business Wire

WP Engine

By

WP Engine

Office 365

By

Microsoft
See more technologies

Bacainn Therapeutics News & Media

Bacainn Therapeutics’ Ashley Mansell to Present on BT032, a Novel First-in-Class NLRP1 and NLRP3 Inhibitor, at the 3rd Inflammasome Therapeutics Digital Summit

CONCORD, Mass.--(BUSINESS WIRE)--Bacainn Therapeutics, Inc., a biotechnology company focused on developing novel therapies that target the innate immune system to address uncontrolled inflammation, today announced that Ashley Mansell, PhD, Senior Director of Research & Development, Bacainn Therapeutics & Principal Investigator, Hudson Institute of Medical Research, will present at the 3rd Inflammasome Therapeutics Summit being held virtually on November 16 – 18. Dr. Mansell’s presentati

Bacainn Therapeutics Presents at ECCO ‘21 Results from Phase 1 Study that Shows BT051, an Oral, Locally-Acting Inhibitor of Neutrophil Trafficking and Activity, Is Safe and Well-Tolerated in Healthy Adults

CONCORD, Mass.--(BUSINESS WIRE)--Bacainn Therapeutics, Inc., a biotechnology company focused on developing novel therapies that target the innate immune system to address uncontrolled inflammation, today presented results at the European Crohn’s and Colitis Organisation’s 2021 Virtual Congress from a Phase 1 study that showed its lead asset BT051 was safe and well-tolerated in healthy adults. BT051 is an oral, locally-acting inhibitor of neutrophil trafficking and activation and is in clinical

Bacainn Therapeutics Reports Positive Topline Results from Phase 1 Study of BT051, a Novel Therapeutic Approach to Treat Inflammatory Diseases Such As Ulcerative Colitis

CONCORD, Mass.--(BUSINESS WIRE)--Bacainn Therapeutics, Inc., a Company developing novel therapies to address uncontrolled inflammation, today announced the successful completion of the company’s Phase 1, first-in-human clinical trial of BT051, a novel, orally administered, gut-selective inhibitor of migration and activation of neutrophils. During active flares of ulcerative colitis, neutrophils migrate into the submucosa and lumen of the colon where they contribute to tissue damage by releasing
Subscribe to "Bacainn Therapeutics" News

Frequently Asked Questions regarding Bacainn Therapeutics

Where are Bacainn Therapeutics’s headquarters?

Bacainn Therapeutics’s headquarters are in 530 Virginia Rd, Ste 300, Concord, Massachusetts, 01742, United States

What is Bacainn Therapeutics’s official website?

Bacainn Therapeutics’s official website is //bacainntherapeutics.com

What is Bacainn Therapeutics’s Revenue?

Bacainn Therapeutics’s revenue is <$5 Million

What is Bacainn Therapeutics’s SIC code?

Bacainn Therapeutics’s SIC: 72,729

What is Bacainn Therapeutics’s NAICS code?

Bacainn Therapeutics’s NAICS: 81299,81

How many employees are working in Bacainn Therapeutics?

Bacainn Therapeutics has <25 employees

What is Bacainn Therapeutics’s industry?

Bacainn Therapeutics is in the industry of: Biotechnology, Pharmaceuticals, Healthcare

What is Bacainn Therapeutics's tech stack?

The technologies that are used by Bacainn Therapeutics are: jQuery Migrate, Microsoft Exchange Online, Cloudflare Security, Business Wire

Who is Bacainn Therapeutics's CEO?

Bacainn Therapeutics's CEO is Ronald Farquhar

See more information about Bacainn Therapeutics

Browse ZoomInfo’s Directories